Downregulation of m6A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non ‐small cell lung cancer

ConclusionsThese findings elucidate that YTHDC2 suppresses tumorigenesis in NSCLC, indicating that YTHDC2 may be a promising therapeutic target for NSCLC.Key pointsSignificant findings of the studyThis study demonstrated that the downregulation of YTHDC2 promotes tumor progression and predicts poor prognosis in non ‐small cell lung cancer (NSCLC).What this study addsYTHDC2 might be a promising therapeutic target for non ‐small cell lung cancer (NSCLC).

Source: Thoracic Cancer - September 20, 2020 Category: Cancer & Oncology Authors: Shulei Sun, Qiang Han, Maoli Liang, Qian Zhang, Jing Zhang, Jie Cao Tags: ORIGINAL ARTICLE Source Type: research